Bortoletto, R.; Garzitto, M.; Piscitelli, F.; Fornasaro, S.; Scipioni, C.; Sepulcri, O.; Fabris, M.; Curcio, F.; Balestrieri, M.; Colizzi, M.
The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis. Brain Sci. 2024, 14, 1230.
https://doi.org/10.3390/brainsci14121230
AMA Style
Bortoletto R, Garzitto M, Piscitelli F, Fornasaro S, Scipioni C, Sepulcri O, Fabris M, Curcio F, Balestrieri M, Colizzi M.
The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis. Brain Sciences. 2024; 14(12):1230.
https://doi.org/10.3390/brainsci14121230
Chicago/Turabian Style
Bortoletto, Riccardo, Marco Garzitto, Fabiana Piscitelli, Stefano Fornasaro, Claudia Scipioni, Orietta Sepulcri, Martina Fabris, Francesco Curcio, Matteo Balestrieri, and Marco Colizzi.
2024. "The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis" Brain Sciences 14, no. 12: 1230.
https://doi.org/10.3390/brainsci14121230
APA Style
Bortoletto, R., Garzitto, M., Piscitelli, F., Fornasaro, S., Scipioni, C., Sepulcri, O., Fabris, M., Curcio, F., Balestrieri, M., & Colizzi, M.
(2024). The Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (EARLY) Study: An Open-Label Feasibility Trial of Ultramicronized-Palmitoylethanolamide Oral Supplementation in Clinical High-Risk State for Psychosis. Brain Sciences, 14(12), 1230.
https://doi.org/10.3390/brainsci14121230
